These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 38615382)

  • 21. Pericarditis and myocarditis after COVID-19 mRNA vaccination in a nationwide setting.
    Yap J; Tham MY; Poh J; Toh D; Chan CL; Lim TW; Lim SL; Chia YW; Lim YT; Choo J; Ding ZP; Foo LL; Kuo S; Lau YH; Lee A; Yeo KK
    Ann Acad Med Singap; 2022 Feb; 51(2):96-100. PubMed ID: 35224605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A narrative review of vaccine pharmacovigilance during mass vaccination campaigns: Focus on myocarditis and pericarditis after COVID-19 mRNA vaccination.
    Piché-Renaud PP; Morris SK; Top KA
    Br J Clin Pharmacol; 2023 Mar; 89(3):967-981. PubMed ID: 36480113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
    Faksova K; Walsh D; Jiang Y; Griffin J; Phillips A; Gentile A; Kwong JC; Macartney K; Naus M; Grange Z; Escolano S; Sepulveda G; Shetty A; Pillsbury A; Sullivan C; Naveed Z; Janjua NZ; Giglio N; Perälä J; Nasreen S; Gidding H; Hovi P; Vo T; Cui F; Deng L; Cullen L; Artama M; Lu H; Clothier HJ; Batty K; Paynter J; Petousis-Harris H; Buttery J; Black S; Hviid A
    Vaccine; 2024 Apr; 42(9):2200-2211. PubMed ID: 38350768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
    Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL
    Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risks of Myocarditis and Pericarditis Following Vaccination with SARS-CoV-2 mRNA Vaccines in Japan: An Analysis of Spontaneous Reports of Suspected Adverse Events.
    Kobayashi H; Fukuda S; Matsukawa R; Asakura Y; Kanno Y; Hatta T; Saito Y; Shimizu Y; Kawarasaki S; Kihara M; Kinoshita N; Umeda H; Noda T; Imamura T; Nishioka Y; Yamaguchi T; Hayashi S; Iguchi T
    Ther Innov Regul Sci; 2023 Mar; 57(2):329-342. PubMed ID: 36310329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System - United States, September 1, 2022 - March 31, 2023.
    Moro PL; Carlock G; Fifadara N; Habenicht T; Zhang B; Strid P; Marquez P
    Vaccine; 2024 Apr; 42(9):2380-2384. PubMed ID: 38462432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance.
    Ruggiero R; Balzano N; Di Napoli R; Mascolo A; Berrino PM; Rafaniello C; Sportiello L; Rossi F; Capuano A
    Front Immunol; 2022; 13():956825. PubMed ID: 36177033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.
    Hause AM; Marquez P; Zhang B; Myers TR; Gee J; Su JR; Blanc PG; Thomas A; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(44):1401-1406. PubMed ID: 36327162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types.
    Li M; Yuan J; Lv G; Brown J; Jiang X; Lu ZK
    J Pers Med; 2021 Oct; 11(11):. PubMed ID: 34834458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic review of spontaneous reports of myocarditis and pericarditis in transplant recipients and immunocompromised patients following COVID-19 mRNA vaccination.
    Lane S; Yeomans A; Shakir S
    BMJ Open; 2022 Jul; 12(7):e060425. PubMed ID: 35777878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study.
    Husby A; Hansen JV; Fosbøl E; Thiesson EM; Madsen M; Thomsen RW; Sørensen HT; Andersen M; Wohlfahrt J; Gislason G; Torp-Pedersen C; Køber L; Hviid A
    BMJ; 2021 Dec; 375():e068665. PubMed ID: 34916207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.
    Gargano JW; Wallace M; Hadler SC; Langley G; Su JR; Oster ME; Broder KR; Gee J; Weintraub E; Shimabukuro T; Scobie HM; Moulia D; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Jul; 70(27):977-982. PubMed ID: 34237049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myocarditis or Pericarditis Events After BNT162b2 Vaccination in Individuals Aged 12 to 17 Years in Ontario, Canada.
    Buchan SA; Alley S; Seo CY; Johnson C; Kwong JC; Nasreen S; Thampi N; Lu D; Harris TM; Calzavara A; Wilson SE
    JAMA Pediatr; 2023 Apr; 177(4):410-418. PubMed ID: 36848096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases.
    Wong HL; Hu M; Zhou CK; Lloyd PC; Amend KL; Beachler DC; Secora A; McMahill-Walraven CN; Lu Y; Wu Y; Ogilvie RP; Reich C; Djibo DA; Wan Z; Seeger JD; Akhtar S; Jiao Y; Chillarige Y; Do R; Hornberger J; Obidi J; Forshee R; Shoaibi A; Anderson SA
    Lancet; 2022 Jun; 399(10342):2191-2199. PubMed ID: 35691322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines.
    Le Vu S; Bertrand M; Jabagi MJ; Botton J; Drouin J; Baricault B; Weill A; Dray-Spira R; Zureik M
    Nat Commun; 2022 Jun; 13(1):3633. PubMed ID: 35752614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination.
    Goddard K; Lewis N; Fireman B; Weintraub E; Shimabukuro T; Zerbo O; Boyce TG; Oster ME; Hanson KE; Donahue JG; Ross P; Naleway A; Nelson JC; Lewin B; Glanz JM; Williams JTB; Kharbanda EO; Katherine Yih W; Klein NP
    Vaccine; 2022 Aug; 40(35):5153-5159. PubMed ID: 35902278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Temporal relationship of myocarditis and pericarditis following COVID-19 vaccination: A pragmatic approach.
    Anastassopoulou C; Hatziantoniou S; Vlachopoulos C; Spanakis N; Tsioufis C; Tsakris A; Lazaros G
    Int J Cardiol; 2022 Jul; 358():136-139. PubMed ID: 35436559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination - PCORnet, United States, January 2021-January 2022.
    Block JP; Boehmer TK; Forrest CB; Carton TW; Lee GM; Ajani UA; Christakis DA; Cowell LG; Draper C; Ghildayal N; Harris AM; Kappelman MD; Ko JY; Mayer KH; Nagavedu K; Oster ME; Paranjape A; Puro J; Ritchey MD; Shay DK; Thacker D; Gundlapalli AV
    MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(14):517-523. PubMed ID: 35389977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hearing disorder following COVID-19 vaccination: A pharmacovigilance analysis using the Vaccine Adverse Event Reporting System.
    Chen C; Fu F; Ding L; Xiao J
    J Clin Pharm Ther; 2022 Nov; 47(11):1789-1795. PubMed ID: 36089844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing the temporal and cause-effect relationship between myocarditis and mRNA COVID-19 vaccines. A retrospective observational study.
    Bianchi FP; Rizzi D; Daleno A; Stefanizzi P; Migliore G; Tafuri S
    Int J Infect Dis; 2024 Apr; 141():106960. PubMed ID: 38365084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.